UBIVE hosts a research team and the National Reference Center (NRC) for Viral Hemorrhagic Fevers (VHF). Research focuses on VHF, in particular Lassa fever caused by Lassa virus, but also Ebola virus. We try to understand the molecular mechanisms involved in the pathogenesis of Lassa fever using animal and primary cell culture models. We study in particular the role of the immune response in the control of infections. We have access to several pathogenic and nonpathogenic arenaviruses thus allowing BSL-4 and BSL-2 studies. We also develop prophylactic and therapeutic approaches against Lassa fever and other arenaviruses. The NRC for VHF links fundamental research and clinical and/or field investigations. Through this activity, new viral strains and biological samples are collected. The NRC also performs applied research and surveillance and expertise activities, like the development of new tools or the study of viral diversity in the wild fauna. Notably, the NRC for FHV has been highly involved in France and on the field in Western Africa during the 2014 Ebola outbreak.
Click to view graph
Connections
Members
Former Members
2000
2000
Name
Position
2018
2020
Vincent Lacoste
CR IP
2014
2018
Justine Schaeffer
PhD Student
2011
2018
Damien Carli
Technician
2013
2017
Sophie Krieger
Post-doc
2012
2018
Jean-Marc Reynes
Permanent Researcher
2012
2016
Audrey Page
Post-doc
2014
2019
Nicolas Baillet
PhD Student
2016
2021
Othmann Merabet
PhD Student
2017
2023
Jimmy Hortion
PhD student
2018
2023
Virginie Borges Cardoso
Research Engineer
2020
2023
Gustave Fourcaud
PhD student
Show all
Projects
Transversal Project
Fundings
Publications
Download-
2024High seroreactivities to orthoebolaviruses in rural Cameroon: a case-control study on non-human primate bites and a cross-sectional survey in rural population, Journal of Infectious Diseases, 2024, pp.jiae399. ⟨10.1093/infdis/jiae399⟩.
-
2023Novel Antiviral Molecules against Ebola Virus Infection., Int J Mol Sci 2023 Sep; 24(19): .
-
2023Hemostasis defects underlying the hemorrhagic syndrome caused by Mammarenaviruses in a cynomolgus macaque model., Blood 2023 Sep; (): .
-
2023Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial, 2023 Apr 15;401(10384):1267-1276. doi: 10.1016/S0140-6736(23)00048-X. Epub 2023 Mar 16. .
-
2023Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys., Nat Commun 2023 Mar; 14(1): 1352.
-
2023A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates., Nat Microbiol 2023 Jan; 8(1): 64-76.
-
2022Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys., Virulence 2022 12; 13(1): 654-669.
-
2022Infection of Human Endothelial Cells with Lassa Virus Induces Early but Transient Activation and Low Type I IFN Response Compared to the Closely-Related Nonpathogenic Mopeia Virus., Viruses 2022 Mar; 14(3): .
-
2021A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains., Sci Transl Med 2021 Jun; 13(597): .
-
2021Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques., Commun Biol 2021 Jan; 4(1): 27.
-
+View full list of publications
Contact
Phone: + 33 4 37 28 24 40 Email: sylvain.baize@pasteur.fr Address 21 avenue Tony Garnier, 69007 LYON France